Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

21.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
21.2K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.6K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the WASF3 Regulatory Complex in Pancreatic Cancer Using Stapled Peptides.

Biochemistry·2026
Same author

CLASPP: A unified model for predicting post-translational modifications.

bioRxiv : the preprint server for biology·2026
Same author

Structural basis of chondroitin sulfate backbone polymer synthesis.

Nature communications·2026
Same author

Mechanistic basis of teichoic acid transport by a gatekeeper flippase.

Nature communications·2026
Same author

Identification and classification of ion channels across the tree of life provide functional insights into understudied CALHM channels.

eLife·2026
Same author

Constrained peptide mimics of the LRRK2 C-terminal Helix inhibits its kinase activity.

Bioorganic chemistry·2026

Related Experiment Video

Updated: Apr 16, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K

Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics.

Laura E Hanold1, Krishnadev Oruganty2, Norman T Ton1

  • 1Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia, United States of America.

Plos One
|March 20, 2015
PubMed
Summary

Researchers designed novel peptide compounds that mimic the epidermal growth factor receptor (EGFR) dimerization arm. These peptides inhibit EGFR activation, showing promise for targeted cancer therapies.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Experiment Videos

Last Updated: Apr 16, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Epidermal growth factor receptor (EGFR) overexpression is common in various carcinomas.
  • Targeted therapies focusing on EGFR are crucial in cancer treatment.
  • Understanding EGFR allosteric activation is key for developing new therapeutic strategies.

Purpose of the Study:

  • To design and synthesize peptide-based compounds that mimic the EGFR dimerization arm.
  • To inhibit the allosteric activation of EGFR using modified peptides.
  • To evaluate the efficacy and stability of these novel peptide inhibitors.

Main Methods:

  • Design of peptide compounds incorporating a triazolyl bridge to constrain the EGFR dimerization arm β-loop.
  • Assessment of proteolytic stability compared to non-modified peptide sequences.
  • Evaluation of inhibitory effects based on methylene unit number and triazolyl bridge orientation.
  • Identification of a specific peptide (EDA2) for further functional analysis.

Main Results:

  • The modified peptides demonstrated significantly improved proteolytic stability.
  • Inhibitory effects were found to be dependent on the triazolyl bridge's structure.
  • A peptide, EDA2, was identified that effectively downregulates EGFR phosphorylation and dimerization.
  • EDA2 reduced cancer cell viability, indicating therapeutic potential.

Conclusions:

  • Triazolyl-bridged peptides can effectively target the EGFR dimerization interface.
  • These novel peptides offer improved stability and potent inhibition of EGFR activation.
  • EDA2 represents a promising biologically active compound for EGFR-targeted cancer therapy.